EUVIMEDEUVIMED entdecken
Crossref

Open trial of recombinant Der f 2 pullulan‐conjugated immunotherapy in cats

Franco Martini iD, Ana Rostaher iD, Claude Favrot iD, Nina M Fischer iD

Veterinary Dermatology · 2024

DOI: 10.1111/vde.13217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Dermatology, 2024. Verfasst von Franco Martini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Arthropod Proteins, Cat Diseases, Dermatitis, Atopic, Glucans. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allermmune HDM (Zenoaq) is a recombinant Dermatophagoides farinae 2 (Der f 2) pullulan‐based immunotherapy vaccine whose efficacy on house dust mite allergic dogs has been demonstrated. There is no published information on its use in cats.

Objectives

The objective of the study was to evaluate the safety and short‐term effects of Allermmune HDM in Dermatophagoides farinae (Df)‐sensitised cats. Materials and Methods Eleven cats diagnosed with atopic skin syndrome received Allermmune weekly for six weeks then monthly for three months (total duration 18 weeks). On Weeks 0, 6 and 18 clinical lesions were assessed by the Feline Dermatitis Extent and Severity Index (FEDESI); owners assessed pruritus with a 10‐cm Visual Analog Scale (pVAS). Concurrent medication use was recorded. The allergen‐specific immunoglobulin (Ig)E were measured before study inclusion with a commercial serological assay.

Results

There were no evident adverse effects. FEDESI and pVAS improved significantly after six weeks ( p = 0.001 and p = 0.01, respectively). The pretreatment Df‐specific IgE levels were significantly higher in the cats with improved clinical scores than in the cats with no clinical score change ( p = 0.009). Conclusions and Clinical Relevance Allermmune HDM may be safe in cats and has the potential to alleviate signs of atopic skin syndrome. Allergen‐specific IgE levels may represent an efficacy marker. Controlled studies of longer duration and larger sample size are worth pursuing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthropod ProteinsCat DiseasesDermatitis, AtopicGlucansAnimalsCatsAllergensAntigens, DermatophagoidesImmunoglobulin EImmunotherapy

Stichwörter der Autor:innen

IgEallergyatopic dermatitiscatsder f 2immunotherapy

Substanzen

AllergensAntigens, DermatophagoidesArthropod ProteinsDermatophagoides farinae antigen f 2GlucansImmunoglobulin Epullulan

Autor:innen und Institutionen

  • Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.

ORCID-Profile: Franco Martini, Ana Rostaher, Claude Favrot, Nina M Fischer

Zitieren

APA

Martini, F., Rostaher, A., Favrot, C., & Fischer, N. M. (2024). Open trial of recombinant Der f 2 pullulan‐conjugated immunotherapy in cats. Veterinary Dermatology. https://doi.org/10.1111/vde.13217

Vancouver

Martini F, Rostaher A, Favrot C, Fischer NM. Open trial of recombinant Der f 2 pullulan‐conjugated immunotherapy in cats. Veterinary Dermatology. 2024. doi:10.1111/vde.13217

BibTeX
@article{Martini2024,
  author = {Martini, Franco and Rostaher, Ana and Favrot, Claude and Fischer, Nina M},
  title = {Open trial of recombinant Der f 2 pullulan‐conjugated immunotherapy in cats},
  journal = {Veterinary Dermatology},
  year = {2024},
  doi = {10.1111/vde.13217}
}
Kostenlos starten →